key: cord-0326871-7pdnf9uh authors: Mazzaferri, F.; Mirandola, M.; Savoldi, A.; De Nardo, P.; Morra, M.; Tebon, M.; Armellini, M.; De Luca, G.; Calandrino, L.; Sasset, L.; D'Elia, D.; Sozio, E.; Danese, E.; Gibellini, D.; Monne, I.; Scroccaro, G.; Magrini, N.; Cattelan, A.; Tascini, C.; MANTICO Working Group,; Tacconelli, E. title: Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron Variant of Concern date: 2022-05-09 journal: nan DOI: 10.1101/2022.05.06.22274613 sha: ade049eae604c74501459686ac2c93f43ead5b15 doc_id: 326871 cord_uid: 7pdnf9uh Background Recent in-vitro data have shown that the activity of monoclonal antibodies (mAbs) targeting SARS-CoV-2 varies according to the Variant of Concern (VOC). No studies have compared the clinical efficacy of different mAbs against Omicron VOC. Methods The MANTICO trial is a non-inferiority randomised controlled trial comparing the clinical efficacy of bamlanivimab/etesevimab, casirivimab/imdevimab, and sotrovimab in outpatients aged 50 or older with early COVID-19. As the patient enrolment was interrupted for possible futility after the onset of the Omicron wave, the analysis was performed according to the SARS-CoV-2 VOC. The primary outcome was COVID-19 progression (hospitalisation, need of supplemental oxygen therapy, or death through day 14). Secondary outcomes included the time to symptom resolution, assessed using the product-limit method. Kaplan-Meier estimator and Cox proportional hazard model were used to assess the association with predictors. Log rank test was used to compare survival functions. Results Overall, 319 patients were included. Among 141 patients infected with Delta, no disease progression was recorded and the time to symptom resolution did not differ significantly between treatment groups (Log-rank Chi-square 0.22, p 0.895). Among 170 patients infected with Omicron (80.6% BA.1, 19.4% BA.1.1), two disease progressions were recorded in the bamlanivimab/etesevimab group and the median time to symptom resolution was 5 days shorter in the sotrovimab group compared to bamlanivimab/etesevimab and casirivimab/imdevimab (HR 0.526 and HR 0.451, 95% CI 0.359 - 0.77 and 95% CI 0.303 - 0.669, p 0.001 and 0.0001, respectively). Conclusions These results confirm the in-vitro data of superiority of sotrovimab versus casirivimab/imdevimab and bamlanivimab/etesivamab in reducing the time to recovery in patients infected with Omicron BA.1 and BA.1.1, while no difference was detected in Delta infections. Casirivimab/imdevimab seems to maintain a role in preventing severe COVID-19 in the Omicron population. Adaptive clinical trials comparing mAbs by VOC should be pursued to promptly inform clinical recommendations. (SARS-CoV-2), has spread globally and poses a major challenge to healthcare systems worldwide. A high 68 incidence of hospitalisation and death due to COVID-19 has been reported among older patients and those Trial design The trial was designed as a pragmatic, randomised, single-blind, non-inferiority, parallel group, multi-centre, 93 controlled trial. Eligible subjects were outpatients aged 50 years or older, presenting with a positive test 94 (either direct antigen or nucleic acid SARS-CoV-2) and mild to moderate COVID-19 symptoms within 4 days The main predictor was the treatment regimen randomised at enrolment (bamlanivimab/etesevimab, casirivimab/imdevimab, and sotrovimab). All patients were assessed at baseline for the following predictors were considered lost to follow-up if they repeatedly did not participate in scheduled visits and could not be 140 contacted by the investigators. Medical evaluation, vital signs recording, and laboratory tests were performed 141 at each visit. If patients missed the visits, they were called by telephone to assess clinical conditions. The SARS-CoV-2 serological status was assessed using LIAISON SARS-CoV-2 TrimericS IgG assay 143 (DiaSorin), an indirect chemiluminescence immunoassay (CLIA) detecting IgG against the spike viral protein 144 in its native trimeric conformation, which includes receptor-binding domain and N-terminal domain sites from 145 the three subunit S1. According to the to manufacturer's instructions, Binding Antibody Units (BAU)/mL ≥ 146 33.8 were considered positive for anti-trimeric spike protein specific IgG antibodies. Nasopharyngeal swabs were processed using MagMAX Viral/Pathogen Nucleic Acid Isolation Kit and 148 KingFisher automated extraction system (ThermoFisher Scientific CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 9, 2022. ; https://doi.org/10.1101/2022.05.06.22274613 doi: medRxiv preprint The first patient was enrolled on December 9, 2021. Overall, 319 patients underwent randomisation by bamlanivimab/etesevimab and casirivimab/imdevimab, as reported in Table 5 . . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The disease progression was recorded in two patients infected with Omicron, who were both randomised to 265 receive bamlanivimab/etesevimab. The absence of COVID-19 progression in two treatment groups (casirivimab/imdevimab and sotrovimab) in the Omicron study population, as well as in all three treatment groups in the Delta study population, could be influenced by the small sample size, the lower intrinsic- . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 9, 2022. ; https://doi.org/10.1101/2022.05.06.22274613 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 9, 2022. ; https://doi.org/10.1101/2022.05.06.22274613 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 9, 2022. ; https://doi.org/10.1101/2022.05.06.22274613 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 9, 2022. ; https://doi.org/10.1101/2022.05.06.22274613 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 9, 2022. ; https://doi.org/10.1101/2022.05.06.22274613 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 9, 2022. ; https://doi.org/10.1101/2022.05.06.22274613 doi: medRxiv preprint Factors associated with hospital admission and critical illness